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ABSTRACT
Background. Thoracoscopic lobectomy for primary lung
cancer has become increasingly popular worldwide due to
several advantages over open lobectomy including reduced
pain, reduced length of hospital stay, and comparable
oncologic outcomes. The costs of thoracoscopic versus
conventional open lobectomy have been compared in
several studies with variable results. We compared the
costs of thoracoscopic versus open lobectomy in lung
cancer patients in Taiwan.
Methods. Patients who underwent lobectomy for primary
lung cancer from the Taiwan National Health Insurance
Research Database (NHIRD) between 2004 and 2010 were
identified. Patient characteristics, operative data, and costs
for each part of the hospitalization for surgery and 30 days
of care after discharge were analyzed.
Results. A total of 5366 patients with complete clinical
data who underwent either conventional open lobectomy
(n = 3166, 59 %) or thoracoscopic lobectomy (n = 2200,
41 %) for primary lung cancer were identified from the
database. Compared with open lobectomy, thoracoscopic
lobectomy was associated with younger age, less comor-
bidity, shorter anesthesia times, and reduced lengths of
hospital stay. Total hospital costs, operative costs, and
other costs were significantly higher in the thoracoscopic
group. The 30-day after discharge costs were significantly
lower in the thoracoscopic group.
Conclusions. Thoracoscopic lobectomy for primary lung
cancer in Taiwan was associated with higher total hospital
costs but lower 30 days after discharge costs than open
lobectomy. These differences may have resulted from
higher operative and instrument costs in the thoracoscopic
group.
Lung cancer is the leading cause of cancer-related death
worldwide.1 Treatment for lung cancer is multidisciplinary,
and surgery offers the best choice for cure in the early
stages of lung cancer. Although some studies have shown
comparative prognoses in select patients who underwent
sublobar anatomic resection (segmentectomy), lobectomy
(either open or thoracoscopic) is still the surgical treatment
of choice for resectable lung cancer.2,3 In addition to
acceptable oncologic outcomes, several benefits of thora-
coscopic lobectomy over conventional open lobectomy
include less acute and chronic pain, shorter duration of
hospital stays, fewer complications, and better tolerance of
adjuvant chemotherapy.4–6
Several studies have analyzed the cost of thoracoscopic
lobectomy compared with other procedures, such as stan-
dard or robot-assisted lobectomy.7–14 The total cost of
thoracoscopic lobectomy was higher than conventional
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lobectomy in some studies but not in the others.7–10,12–14 In
this cost-sensitive medical care era, cost may play a role
when choosing the type of lobectomy in addition to prog-
nosis and other factors.
The Taiwan National Health Insurance Research Data-
base (NHIRD), managed by the National Health Research
Institute of Taiwan, consists of detailed health care data
from 99 % of the residents living in Taiwan. We used this
population-based database to compare the cost of the tho-




The NHIRD was used as the data source for this study.
The released database was used strictly for research pur-
poses, and all information that could potentially identify an
individual patient was encrypted. This study was exempt
from full review by the Internal Review Board in Chan-
ghua Christian Hospital.
The NHIRD, established in 1997, includes nearly 99 %
of the 23 million inhabitants of Taiwan and is managed by
the National Health Research Institute of Taiwan. It pro-
vides clinical health information, including demographic
data, primary and secondary diagnoses, clinical data, out-
patient and inpatient visits, costs of services and
procedures, and treatment patterns. The diagnosis codes
used in this study were obtained from the International
Classification of Disease, Tenth Revision, Clinical Modi-
fication code [ICD-10-CM].
Patient Selection and Cost Data
Between 2004 and 2010, 65,976 patients were identified
with the diagnosis of lung cancer using the diagnostic
codes C34.0, C34.1, C34.2, C34.3, C34.8, and C34.9. A
total of 13,846 patients were excluded because of incom-
plete clinical data. Among the remaining 52,130 patients,
5366 (10.3 %) patients underwent either open lobectomy
or thoracoscopic lobectomy and were enrolled in the study.
Patient characteristics included in this study were age,
gender, Charlson score, cell type, and clinical stage. Their
histology was described according to the World Health
Organization classification. All patients were staged
according to the 6th edition of the TNM staging system,
published in 1997. The hospitalization and operative data
included anesthesia times, lengths of hospital stay, the
periods of postoperative chest tube drainage, and surgical
mortalities. The cost data included operating room, anes-
thesia, nursing, pharmacy, intensive care unit, ordinary
ward, laboratory, treatments, and other costs. The medical
cost for each patient within 30 days after discharge also
was extracted from the database. All costs extracted from
the database were calculated in New Taiwan dollars (NTD/
TWD) and converted to United States dollars (USD) using
the conversion, 1 USD = 30 TWD.
Statistical Analysis
All continuous data were expressed as mean ± standard
deviation. The Charlson score was used to quantify pre-
existing comorbidity as a means of classifying clinical
comorbidities, because it is widely used for risk adjustment
in administrative datasets.15 Surgical mortality was defined
as death occurring during the same hospitalization or
within 30 days after the operation. Comparisons of cate-
gorical data between the two groups were made using v2 or
the Fisher exact test. Continuous data were compared using
the two-tailed t test. Statistical analysis was considered
significant at p\ 0.05. The SAS software (SAS System for
Windows, version 9.2; SAS Institute, Cary, NC) was used
to perform the statistical analysis.
RESULTS
Patient Characteristics
Among the 5366 lung cancer patients who underwent
lobectomy between 2004 and 2010, 3166 (59 %) under-
went conventional open lobectomy and 2200 (41 %) had
thoracoscopic lobectomy. Patient demographics and tumor
characteristics are listed in Table 1. The average age in the
open lobectomy group was 66.63 ± 11.11 years compared
with 61.70 ± 11.02 years in thoracoscopic lobectomy
group (p\ 0.0001). There were more males in the open
group than in the thoracoscopic (56.95 vs. 45.27 %). The
mean Charlson score was higher in the open group com-
pared with the thoracoscopic group (5.58 ± 3.22 vs.
4.87 ± 2.97; p\ 0.0001). The most common tumor cell
type was adenocarcinoma, which accounted for 66.23 % of
tumors in the open group and 79.23 % in the thoracoscopic
group. The patients in thoracoscopic group had earlier
TNM staging compared with patients in open group.
Perioperative Details
Perioperative details and patient outcomes are listed in
Table 2. The average anesthesia time was longer in the
open group compared with the thoracoscopic group
(5.55 ± 1.94 vs. 5.40 ± 1.79 h; p = 0.033). The average
length of hospital stay was 17.49 ± 15.89 days in the open
group and 13.00 ± 8.7 days in the thoracoscopic group.
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The average duration of chest tube placement after oper-
ation was longer in the open group compared with the
thoracoscopic group (8.68 ± 5.10 vs. 6.44 ± 4.42 days,
p\ 0.001). The surgical mortality was greater in open
group compared with the thoracoscopic group (1.04 vs.
0.41 %; p = 0.0096).
Cost Profile
The detailed hospital costs are listed in Table 3. The total
cost of the index hospitalization for lobectomy surgery was
higher in the thoracoscopic group ($6,574.1 ± $3,605.9 vs.
$6,329.9 ± $4434.3; p = 0.026). Regarding breakdown of
total cost, only the operative costs and other cost were
higher in the thoracoscopic group. The other cost included
any instruments or equipment used other than operative
costs, such as surgical stapling devices, energy-based vas-
cular sealing and cutting devices, hemostat agents, and
tissue adhesives. The 30-day after discharge costs involved
any medical costs within 30 days after discharge and
included any hospital emergency room visits, outpatient
department visits, or any hospital or clinic visits other than
the hospital where the patient underwent lobectomy. This
cost was significantly higher in the open group compared
with the thoracoscopic group ($831.90 ± $1759.90 vs.
$612.80 ± $1401.00, p\ 0.001).
Comment
Our study showed that the total hospital costs were
higher in the thoracoscopic lobectomy group compared
with the open lobectomy group, although the 30-day after
discharge costs were significantly lower in the thoraco-
scopic group. Of the 41 % of patients who underwent
thoracoscopic lobectomy for lung cancer treatment in our
study, most were females and younger in age compared
with the open group.
Lobectomy with radical lymph node dissection is still
the mainstream treatment for resectable lung cancers
worldwide. In a large study of lung cancer patients in
Taiwan, the majority (64.1 %) underwent lobectomy.16
The thoracoscopic approach used in lobectomy has become
more popular due to greater familiarity with this technique,
comparable oncologic outcomes, and distinct advantages
over open lobectomy, such as shorter duration of adjuvant
chemotherapy, better patient tolerance, less pain, and
shorter length of hospital stay.




No. of patients 3166 (59 %) 2200 (41 %)
Age (year)
(mean ± SD)
63.63 ± 11.11 61.70 ± 11.02 \0.0001
Gender \0.0001
Male 1803 (56.95 %) 996 (45.27 %)
Female 1363 (43.05 %) 1204
(54.73 %)
Charlson score 5.58 ± 3.22 4.87 ± 2.97 \0.0001
Cell type \0.0001
Adenocarcinoma 2097 (66.23 %) 1743
(79.23 %)
SqCC 670 (21.16 %) 258 (11.73 %)
Small cell 23 (0.73 %) 10 (0.45 %)
Large cell 49 (1.55 %) 15 (0.68 %)
Others 327 (10.33 %) 174 (7.91 %)
Pathologic stage \0.0001
T1 1136 (35.88 %) 1187
(53.95 %)
T2 1611 (50.88 %) 826 (37.55 %)
T3 268 (8.46 %) 113 (5.14 %)
T4 126 (3.98 %) 68 (3.09 %)
Unknown 25 (0.79 %) 6 (0.27 %)
N \0.0001
N0 2175 (68.7 %) 1790
(81.36 %)
N1 333 (10.52 %) 188 (8.55 %)
N2 560 (17.69 %) 195 (8.86 %)
N3 69 (2.18 %) 20 (0.91 %)
Unknown 29 (0.92 %) 7 (0.32 %)
M \0.0001
M0 2988 (94.38 %) 2131
(96.86 %)
M1 163 (5.15 %) 69 (3.14 %)
Unknown 15 (0.47 %) 0 (0 %)
SqCC squamous cell carcinoma
TABLE 2 Perioperative details and patient outcomes
Variables Open Thoracoscope p value
Anesthesia time (hour)
(mean ± SD)
5.55 ± 1.94 5.40 ± 1.79 0.0033
Anesthesia time (hour) 0.0377
\4.5 790 (24.95 %) 548
(24.91 %)





C6.5 850 (26.85 %) 542
(24.64 %)
Length of stay (days)
(mean ± SD)
17.49 ± 15.89 13.00 ± 8.79 \0.0001
Chest tube (days)
(mean ± SD)
8.68 ± 5.10 6.44 ± 4.42 \0.0001
Surgical mortality 33 (1.04 %) 9 (0.41 %) 0.0096
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A study of a general thoracic surgery registry database
performed between 1999 and 2006 revealed that only 20 %
of patients underwent thoracoscopic approach for primary
lung cancer.17 Another recent national database analysis
found that approximately 39 % of lung cancer patients
underwent thoracoscopic lobectomy.18 In our study, ade-
nocarcinoma was the predominant cell type in both open
and thoracoscopic groups and tumor size tended to be
smaller in the thoracoscopic group and the thoracoscopic
group also had a lower T stage. The indication of thora-
coscopic lobectomy in Taiwan included small peripheral
lung cancer and that contributed to smaller tumor size in
thoracoscopic group compared with open group.
The cost of thoracoscopic lobectomy compared with
conventional open lobectomy has been analyzed in several
studies ranging from small sample-sized studies performed
at a single institution to large studies using a national
database. Some studies have shown lower costs using
thoracoscopic lobectomy. Park and colleagues compared
robotic, video-assisted thoracoscopic surgery (VATS), and
thoracotomy approaches to pulmonary lobectomy and
found lower costs and shorter hospital stays in the VATS
group.7 Casali and Walker reported that thoracoscopic
lobectomy had higher surgical costs but lower total costs
and this was felt to be related to the shorter hospital stays in
the thoracoscopic lobectomy group.8 Burfeind and col-
leagues, in a retrospective analysis of primary lung cancer
patients who received either thoracoscopic or open lobec-
tomy, demonstrated less costs for thoracoscopic lobectomy
in all phases of patient care.9 Swanson et al. also analyzed
the cost differences between thoracoscopic and open
lobectomy groups from a multi-institutional database and
revealed that the VATS approach was less costly with
fewer complications, shorter anesthesia times, and shorter
hospital stays than open lobectomy.12 Fajah and colleagues
studied patients who underwent lobectomy not just for lung
cancer and further analyzed the 90-day cost after dis-
charge.13 They found that the thoracoscopic group had
significantly lower total 90-day index hospitalization costs
and outpatient costs. In contrast, Gopaldas et al. examined
the Nationwide Inpatient Sample database of the United
States comparing VATS to open thoracotomy lobectomy
and found that the cost of VATS lobectomy tended to be
higher than open thoracotomy lobectomy, but the differ-
ence was not statistically significant.10 The VATS
lobectomy group patients had similar hospital stays and
more intraoperative complications compared with the open
thoracotomy group. Recently, a study reported by Alpay
et al. showed that VATS lobectomy costs were greater than
costs from thoracotomy lobectomy.14 The authors con-
cluded that these findings may have resulted from lower
bed fees and higher disposable instrument costs. The total
cost of thoracoscopic versus open lobectomy was variable
in the above studies. These findings may be explained by
different charge policies regarding surgical, anesthesia, and
hospital fees, and variable professional and operative fees.
In Taiwan, the medical expenses are regulated by the
government under the National Health Insurance Admin-
istration, Ministry of Health and Welfare. Although the
fees for lobectomy and mediastinal lymph node dissection
differ between thoracoscopic versus open approaches, the
same procedure in different hospitals costs the same. We
found that the operative cost was significant higher in the
thoracoscopic group compared with the open group. The
most important factor affecting anesthesia cost in our study
was anesthesia time. Both anesthesia time and anesthesia
cost were significantly higher in the open group compared
with the thoracoscopic group. In our study, the length of
hospital stay was significantly higher in the open group and
that finding could have contributed to the higher cost of
ordinary ward, ICU, nursing, and pharmacy costs. The
other costs and operative costs were significantly higher in
the thoracoscopic group, which made the total cost sig-
nificantly higher in the thoracoscopic group. Similar to the
study performed by Alpay et al., lower bed and manpower
costs with higher disposable instrument costs may explain
the higher total hospital costs in the thoracoscopic group in
our study despite the shorter hospital stays and anesthesia
times.14
Few studies have analyzed the cost of medical needs
after discharge. One of the factors that may have influenced
the after-discharge cost in our study was the postoperative
complication rate, which may have resulted in more out-
patient visits or readmissions. Farjah et al. analyzed the
costs up to 90 days after discharge and also found a sig-
nificantly lower cost in the thoracoscopic group.13 As they
reported, outpatient use and readmissions accounted for
TABLE 3 Cost profile
Variable Open (USD) Thoracoscope
(USD)
p value
Total cost 6329.9 ± 4434.3 6574.1 ± 3605.9 0.0266
Operative 1638.1 ± 310.5 1897.2 ± 362.8 \0.0001
Anesthesia 548.9 ± 211.5 534.1 ± 188.9 0.0071
Nursing 614.7 ± 729.5 447.7 ± 499.4 \0.0001
Pharmacy 501.6 ± 1156.9 349.6 ± 1388.5 \0.0001
ICU 217.2 ± 401.2 144.8 ± 293.2 \0.0001
Ordinary ward 250.4 ± 227.7 192.4 ± 122.7 \0.0001
Labs 893.6 ± 648.2 773.4 ± 551.2 \0.0001
Treatments 496.1 ± 788.3 358.4 ± 538.0 \0.0001
Others 1169.2 ± 1094.8 1876.6 ± 1033.8 \0.0001
30-day after
discharge cost
831.9 ± 1759.9 612.8 ± 1401.0 \0.0001
USD United States dollars
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near 16 % of the total 90-day costs after lobectomy. In our
study, the 30-day after-discharge cost was significantly
lower in the thoracoscopic group. This may be explained
by less pain experienced by the patients and, thus, fewer
required outpatient visits and analgesic agents along with
fewer complications and less need for readmission.
The strength of our study was its large patient size,
which included nearly 99 % of the resident population in
Taiwan. This factor may have balanced the effects due to
the differing economic status among patients and the dif-
ferent hospital volumes (i.e., between a medical center vs. a
regional hospital). In addition, the 30-day after-discharge
cost included all medical expenses incurred by the same
patient at different hospitals.
Our study also had several limitations. The data were
conducted on a retrospective cohort, based on diagnostic
codes and prescription histories. Registry bias could not be
fully excluded, but its influence may have been minimized
by the review of the medical expenses conducted by gov-
ernment experts. In addition, although 13,846 (20.9 %)
patients were excluded because of incomplete data, com-
pared with other population databases, the percentage of
patients with complete data was relatively high in our
database.
CONCLUSIONS
This retrospective study from a large Taiwanese data-
base demonstrated that total hospital costs were higher in
the thoracoscopic lobectomy group compared with the
open lobectomy group and resulted primarily from higher
operative and other costs. The 30-day after discharge costs
were significantly lower in the thoracoscopic group.
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